Neuroblastoma-specific cytotoxicity mediated by the Mash1-promoter and E. coli purine nucleoside phosphorylase

Pediatric Blood and Cancer

Volumn 44, Issue 1, 2005, Pages 77-84

  Arvidsson, Yvonne ^a,e   Sumantran, Venu ^a,b   Watt, Fujiko ^a,c   Uramoto, Hidetaka ^a,d   Funa, Keiko ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Bharati Vidyapeeth Deemed University   (India)

^c CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

E. coli PNP; Gene therapy; HASH1; Mash1; Neuroblastoma; Tissue specific

Indexed keywords

FLUOROADENINE 9 BETA ARABINOFURANOSIDE; PRODRUG; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; ENHANCER REGION; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR CLONING; NEUROBLASTOMA; PRIORITY JOURNAL; PROMOTER REGION; SUICIDE GENE THERAPY;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL DEATH; DNA-BINDING PROTEINS; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; HELIX-LOOP-HELIX MOTIFS; HUMANS; NEUROBLASTOMA; PROMOTER REGIONS (GENETICS); PURINE-NUCLEOSIDE PHOSPHORYLASE; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 10044296346     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20163     Document Type: Article

References (43)

1. Berthold F, Hero B. Neuroblastoma. Current drug therapy recommendations as part of the total treatment approach. Drugs 2000;59:1261-1277.
2. Johnson JE, Birren SJ, Anderson DJ. Two rat homologs of Drosophila achaete-scute specifically expressed in neuronal precursors. Nature 1990;346:858-861.
3. Lo LC, Johnson JE, Wuenschell CW, et al. Mammalian achaetescute homolog 1 is transiently expressed by spatially restricted subsets of early neuroepithelial and neural crest cells. Genes Dev 1991;5:1524-1537.
4. Guillemot F, Lo LC, Johnson JE, et al. Mammalian achaete-scute homolog 1 is required for the early development of olfactory and autonomic neurons. Cell 1993;75:463-476.
5. Ahmad I, Dooley CM, Afiat S. Involvement of Mash1 in EGF-mediated regulation of differentiation in the vertebrate retina. Dev Biol 1998;194:86-98.
6. Ichimiya S, Nimura Y, Seki N, et al. Downregulation of hASH1 is associated with the retinoic acid-induced differentiation of human neuroblastoma cell lines. Med Pediatr Oncol 2001;36:132-134.
7. Gestblom C, Grynfeld A, Ora I, et al. The basic helix-loop-helix transcription factor dHAND, a marker gene for the developing human sympathetic nervous system, is expressed in both high- and low-stage neuroblastomas. Lab Invest 1999;79:67-79.
8. Soderholm H, Ortoft E, Johansson I, et al. Human achaete-scute homolog 1 (HASH-1) is downregulated in differentiating neuroblastoma cells. Biochem Biophys Res Commun 1999;256:557-563.
9. Balicki D, Reisfeld RA, Pertl U, et al. Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma. Proc Natl Acad Sci USA 2000;97:11500-11504.
10. Bowman L, Grossman M, Rill D, et al. IL-2 adenovector-transducted autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 1998;92:1941-1949.
11. Bowman L, Grossman M, Rill D, et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 1998;9:1303-1311.
12. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 inpatients with advanced or refractory neuroblastoma. Blood 2003;101:1718-1726.
13. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, et al. In vivo gene therapy for prostate cancer: Preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther 1998;9:1617-1626.
14. Mohr L, Shankara S, Yoon SK, et al. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology 2000;31:606-614.
15. Gadi VK, Alexander SD, Kudlow JE, et al. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther 2000;7:1738-1743.
16. Parker WB, King SA, Allan PW, et al. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum Gene Ther 1997;8:1637-1644.
17. Puhlmann M, Gnant M, Brown CK, et al. Thymidine kinase-deleted Vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther 1999;10:649-657.
18. Sorscher EJ, Peng S, Bebok Z, et al. Tumor cell bystander killing in colonie carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther 1994;1:233-238.
19. Hughes BW, Wells AH, Bebok Z, et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res 1995;55:3339-3345.
20. Parker WB, Allan PW, Shaddix SC, et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 1998;55:1673-1681.
21. Fulda S, Kufer MU, Meyer E, et al. Sensitization for death receptor-or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865-5877.
22. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000;6:529-535.
23. Teitz T, Lahti JM, Kidd VJ. Aggressive childhood neuroblastomas do not express caspase-8: An important component of programmed cell death. J Mol Med 2001;79:428-436.
24. Krohne TU, Shankara S, Geissler M, et al. Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology 2001;34:511-518.
25. Lockett LJ, Molloy PL, Russel PJ, et al. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin Cancer Res 1997;11:2075-2080.
26. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
27. Verma-Kurvari S, Savage T, Smith D, et al. Multiple elements regulate Mash1 expression in the developing CNS. Dev Biol 1998;197:106-116.
28. Chen H, Biel MA, Borges MW, et al. Tissue-specific expression of human ashaete-scute homologue-1 in neuroendocrine tumors: Transcriptional regulation by dual inhibitory regions. Cell growth diff 1997;8:677-686.
29. Guillemot F, Joyner AL. Dynamic expression of the murine achaete-scute homolog (MASH-1) in the developing nervous system. Mech Dev 1993;42:171-185.
30. Sommer L, Shah N, Rao M, et al. The cellular function of MASH1 in autonomic neurogenesis. Neuron 1995;15:1245-1258.
31. Ball DW, Azzoli CG, Baylin SB, et al. Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Proc Natl Acad Sci USA 1993;90:5648-5652.
32. Verma-Kurvari S, Savage T, Gowan K, et al. Lineage-specific regulation of the neural differentiation gene MASH1. Dev Biol 1996;180:605-617.
33. Chen H, Thiagalingam A, Chopra H, et al. Conservation of the Drosophila lateral inhibition pathway in human lung cancer: A hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression. Proc Natl Acad Sci USA 1997;94:5355-5360.
34. Meredith A, Johnson JE. Negative autoregulation of Mash expression in CNS development. Dev Biol 2000;222:336-346.
35. Takebayashi K, Sasai Y, Sakai Y, et al. Structure, chromosomal locus, and promoter analysis of the gene encoding the mouse helix-loop-helix factor HES-1. Negative autoregulation through the multiple N box elements. J Biol Chem 1994;269:5150-5156.
36. Ohsako S, Hyer J, Panganiban G, et al. Hairy function as a DNA-binding helix-loop-helix repressor of Drosophila sensory organ formation. Genes Dev 1994;8:2743-2755.
37. Van Doren M, Bailey AM, Esnayra J, et al. Negative regulation of proneural gene activity: Hairy is a direct transcriptional repressor of achaete. Genes Dev 1994;8:2729-2742.
38. Sasai Y, Kageyama R, Tagawa Y, et al. Two mammalian helix-loop-helix factors structurally related to Drosophila hairy and Enhancer of split. Genes Dev 1992;6:2620-2634.
39. Jonk LJ, Itoh S, Heldin CH, et al. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem 1998;273:21145-21152.
40. Shah NM, Groves AK, Anderson DJ. Alternative neural crest cell fates are instructively promoted by TGFbeta superfamily members. Cell 1996;85:331-343.
41. Shabat D, Lode HN, Pertl U, et al. In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy. Proc Natl Acad Sci USA 2001;98:7528-7533.
42. Narita M, Bahar R, Hatano M, et al. Tissue-specific expression of a suicide gene for selective killing of neuroblastoma cells using a promoter region of the NCX gene. Cancer Gene Ther 2001;8:997-1002.
43. Blackwood EM, Kadonaga JT. Going the distance: A current view of enhancer action. Science 1998;281:61-63.